Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity.

PPP1R1B (also known as DARPP-32) levels were significantly altered across disease stages ( Supplementary Table 2 , P = 0.042) and showed a trend towards decreased levels in late HD compared with early/mid HD groups (MD = 0.3682, 95% CI: −0.029–0.765, P = 0.076).

also in 53,322 other papers

1B , MD = 0.601, 95% CI: 0.133–1.070, ## P = 0.008) and a strong trend towards a reduction in late HD compared with controls was observed but did not reach post hoc significance (MD = 0.461, 95% CI: −0.007–0.930, P = 0.055).

also in 5,725 other papers

We also observed trends towards increased levels DRD1 (OR = −3.719, 95% CI: −8.216 to −0.194, P = 0.062) and ALB (OR = −5.534, 95% CI: −12.505 to −0.258, P = 0.068), and decreased levels of BDNF (OR = 2.649, 95% CI: 0.13–5.716, P = 0.056) in HD mutation carriers but these did not reach statistical significance.

also in 111,027 other papers